NCT05537233View on ClinicalTrials.gov

ADJUnct Semaglutide Treatment in Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

August 6, 2024

Study Completion Date

August 6, 2024

Conditions
Type 1 DiabetesObesity
Interventions
DRUG

Semaglutide

Semaglutide up to 1 mg per week in addition to standard closed-loop therapy

DRUG

Placebo

Injection placebo up to 1 mg per week in addition to standard closed-loop therapy

Trial Locations (4)

48202

Henry Ford Hospital, Detroit

50265

Iowa Diabetes Research Center, West Des Moines

80045

Barbara Davis Center for Diabetes, Aurora

97239

Harold Schnitzer Diabetes Health Center, Portland

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

Viral N. Shah

OTHER